Cemsidomide and dexamethasone for relapsed/refractory multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This clinical trial tests a new combination of two medicines (cemsidomide and dexamethasone) for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. The goal is to see if this new drug can help control the cancer when other options have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have multiple myeloma that has returned or stopped responding to treatment and is measurable on tests
- You have already tried at least 3 different treatment plans, including specific drugs like lenalidomide, bortezomib, daratumumab, and a T-cell engager or CAR-T therapy
- You do not have myeloma that has spread to your brain or spinal cord
- You do not have certain other conditions like amyloidosis, POEMS syndrome, or myelodysplastic syndrome
- Your body organs (kidney, liver, etc.) are working well enough, and any side effects from past treatments have mostly gone away
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding dexamethasone to an antibody-based combination therapy works better for multiple myeloma that has come back after previous treatments. If you have had 1 to 3 prior therapies and are eligible for one of two standard drug regimens, this study may help find the best approach for you.
This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.
This trial tests a new drug for people with multiple myeloma, a type of blood cancer. It's for those who are newly diagnosed or whose cancer has come back or stopped responding to treatment. The goal is to see if the drug can control the disease.
This trial tests a combination of three drugs (elotuzumab, iberdomide, and dexamethasone) for multiple myeloma that has come back after treatment with a type of CAR T-cell therapy called ide-cel. It aims to see if this new combination can help people who have already tried several other treatments.
This trial tests different dosing schedules of three drugs (belantamab mafodotin, bortezomib, and dexamethasone) together to treat multiple myeloma that has come back or stopped responding to previous treatments. The goal is to find a dosing plan that works well and is tolerable for patients.
This trial tests a new treatment called BMS-986393 (a type of CAR T-cell therapy) compared to standard treatments for adults with multiple myeloma that has come back or is not responding to therapy, and who have already been treated with lenalidomide (Revlimid). The goal is to see if the new treatment works better.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.